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Abstract The p53 tumor suppressor protein induces cell cycle
arrest or apoptosis in response to cellular stresses. We have
identi¢ed PRG3 (p53-responsive gene 3), which is induced spe-
ci¢cally under p53-dependent apoptotic conditions in human co-
lon cancer cells, and encodes a novel polypeptide of 373 amino
acids with a predicted molecular mass of 40.5 kDa. PRG3 has
signi¢cant homology to bacterial oxidoreductases and the apo-
ptosis-inducing factor, AIF, and the gene was assigned to chro-
mosome 10q21.3^q22.1. Expression of PRG3 was induced by
the activation of endogenous p53 and it contains a p53-respon-
sive element. Unlike AIF, PRG3 localizes in the cytoplasm and
its ectopic expression induces apoptosis. An amino-terminal de-
letion mutant of PRG3 that lacks a putative oxidoreductase
activity retains its apoptotic activity, suggesting that the oxido-
reductase activity is dispensable for the apoptotic function of
PRG3. The PRG3 gene is thus a novel p53 target gene in a
p53-dependent apoptosis pathway. 3 2002 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
Key words: p53; Target gene; Cloning; Apoptosis;
Oxidoreductase; Transcription
1. Introduction
The p53 gene is one of the most frequently altered genes in
a wide variety of tumor types, indicating its importance in cell
growth control and tumorigenesis [1,2]. The loss of wild-type
p53 activity removes important controls on cell cycle regula-
tion, apoptosis, and maintenance of genomic integrity in cul-
tured cells [3], and contributes to tumor development [4]. The
limited developmental abnormalities associated with the ma-
jority of p53 (3/3) mice indicate that p53 may be dispensable,
to a large extent, for the apoptotic processes occurring during
normal embryo development. However, under conditions of
cellular stress that endanger the integrity of the genome, p53
becomes crucial in restricting inappropriate cell proliferation
[3,5^7]. Cellular stresses that can induce p53-mediated apopto-
sis include DNA damage [8,9], deregulated oncogene expres-
sion [10^14], hypoxia [15], ribonucleotide depletion [16], and
oxidative stress [17]. In normal cells, under physiological con-
ditions the p53 tumor suppressor protein is present at a low
level because of a short half-life due to rapid turnover medi-
ated by ubiquitination and proteolysis [18,19]. After DNA
damage, wild-type p53 accumulates and becomes an active
transcription factor that binds a speci¢c DNA sequence in
the promoter of speci¢c genes to activate transcription [20^
23].
The p53-responsive genes (PRGs) so far identi¢ed are those
involved in cell cycle control, such as p21 [21,24], GADD45
[25], B99 [26] and 14-3-3c [27]. In addition, an increasing
number of PRGs associated with the apoptotic process have
been isolated [28]. These include Bax [29], Fas [30^32], IGF-
BP3 [20], Dr5/KILLER [33], PAG608 [34], PRGs [35], PIDD
[36], DRAL [37], p53AIP1 [1], PERP [2], Noxa [38], and p53-
inducible genes (PIGs) [39]. One of the PIGs, PIG3, encodes a
quinone oxidoreductase, suggesting that PIG3 is possibly in-
volved in intracellular redox regulation and the induced stim-
ulation of reactive oxygen species would result in disruption
of mitochondrial integrity and apoptosis. Alterations in mito-
chondrial membrane structure and function have been shown
to play a crucial role in caspase-9-dependent apoptosis [40] by
releasing apoptotic factors from mitochondria, including cy-
tochrome c. Recently, mitochondria have been found to re-
lease a new class of proapoptotic factors, apoptosis-inducing
factor (AIF), in response to various stimuli. AIF is a ubiqui-
tously expressed £avoprotein with signi¢cant homology to
bacterial oxidoreductases [41] and has NADH oxidase activity
[42]. At the induction of apoptosis AIF translocates through
the outer mitochondrial membrane to the cytosol and to the
nucleus, resulting in the induction of nuclear chromatin con-
densation and large DNA fragmentation in a caspase-inde-
pendent manner [41,43,44]. This AIF-dependent, caspase-in-
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dependent apoptosis has been shown to be essential to the
cavitation of embryoid bodies [45]. Here we report that
PRG3 encodes an apoptotic cytoplasmic protein with signi¢-
cant homology to bacterial oxidoreductase and to AIF re-
leased from mitochondria. Thus, PRG3 may provide a novel
mechanism for p53-dependent apoptosis.
2. Materials and methods
2.1. Cell culture and cloning
Saos2, H1299, and HeLa cells were maintained at 5% CO2 in Dul-
becco’s modi¢ed Eagle’s medium (Life Technologies, Rockville MD,
USA) supplemented with 10% fetal calf serum (FCS). EB1 cells were
maintained at 5% CO2 in McCoy’s 5A medium (Life Technologies)
supplemented with 10% FCS. TK6 cells were maintained at 5% CO2
in RPMI 1640 medium (Life Technologies) supplemented with 10%
FCS. A cDNA library, prepared from poly(A)þ RNA extracted from
EB1 cells treated with 0.1 mM ZnCl2 for 9 h was screened with the
original PRG3 cDNA fragment as a probe. This screen yielded a few
clones containing the entire open reading frame of PRG3 (GenBank
accession number AF337957). The NH2-terminus (1^37) deletion mu-
tant PRG3 was constructed by polymerase chain reaction using the
forward primer 5P-GGGGAATTCATGCTGGTGGACATGAAG-
GACTCC-3P and the reverse primer 5P-GGGCTCGAGTCAAGGA-
GACTGCCTCATGGT-3P. The coding region was subcloned into
mammalian expression vectors pcDNA3.1 or pCMV-FLAG2. A lu-
ciferase reporter plasmid was constructed with pTI-Luc [46] by insert-
ing a p53-binding site element in the PRG3 gene: 5P-AGA-
CATGCCTGGAAGCAGTAATTTTAAACAAGCTT-3P.
2.2. Fluorescence in situ hybridization (FISH)
A genomic clone of the PRG3 gene was isolated from a bacterial
arti¢cial chromosome (BAC) human genomic library with a cDNA
probe under high stringency conditions (65‡C 0.1Usaline sodium
citrate (SSC), 0.1% sodium dodecyl sulfate (SDS)). The identity of a
positive BAC clone was con¢rmed by partial sequence analysis (data
not shown). FISH was performed using established methods on meth-
otrexate/thymidine or thymidine/bromodeoxyuridine-synchronized,
phytohemagglutinin-stimulated, normal peripheral blood lymphocytes
[47]. The probe was preincubated for 30 min with a mixture of soni-
cated human DNA (Sigma, St. Louis, MO, USA) and Cot1 DNA
(Life Technologies) to reduce the background. The stained slides were
counterstained with 4,6-diamidino-2-phenylindole (DAPI) and actino-
mycin D (for a DA-DAPI banding pattern) or propidium iodide (PI;
for an R banding pattern), mounted in an antifade medium and an-
alyzed under a Zeiss Axioplan 2TM microscope. Approximately
50 metaphase spreads were examined. At least one speci¢c probe
signal was present in more than 90% of the mitoses examined. Images
were captured using a cooled CCD camera (Photometrics PXL1400,
Photometrics, Tucson, AZ, USA). Digital alignment of the images
from each £uorescence was applied after registration calibration
through a triple band pass ¢lter (FITC/Texas Red/DAPI) using com-
mercial software (Electronic Photography, Biological Detection Inc.,
Pittsburgh, PA, USA) to minimize the registration error.
2.3. Northern blotting
Total RNA was extracted with Trizol (Life Technologies). TK6
cells were treated with 0.2 Wg/ml doxorubicin for 15 h, and total
RNA was isolated. 20 Wg of total RNA was separated on a 1% aga-
rose/1UMOPS/2% formaldehyde gel and transferred to nylon mem-
branes (Hybond-N, Amersham, Piscataway, NJ, USA) in 10USSPE
and UV cross-linked to the membrane before pre-hybridizing. Filters
were hybridized with random-primed 32P-labeled probes in QuickHy-
bri Solution (Stratagene, La Jolla, CA, USA) at 68‡C for 1 h. Hy-
bridized blots were washed twice at high stringency in a solution of
0.1USSPE/0.1% SDS at 55 ‡C and exposed to a Kodak X-Omat AR
¢lm (Fisher Scienti¢c, Pittsburgh, PA, USA). Tissue-speci¢c expres-
sion of the human PRG3 gene was evaluated using human multiple
tissue Northern blots (Clontech, Palo Alto, CA, USA). Membranes
were hybridized with radiolabeled human PRG3 cDNA probes in
ExpressHyb Solution (Clontech) at 68‡C for 2 h. Hybridized blots
were washed twice at high stringency in a solution of 0.1USSC/
0.1% SDS at 50‡C. Autoradiography was performed for 1^3 days
using Kodak X-Omat AR ¢lm.
2.4. Functional assay for PRG3
The cellular localization of the PRG3 protein was determined by
transient transfection of a FLAG-tagged PRG3 expression plasmid
Fig. 1. Identi¢cation of the PRG3 gene. A: DNA and predicted amino acid sequence of PRG3. DNA sequence revealed that PRG3 consists of
373 amino acids. The in-frame stop codon in the 5P-non-coding region is underlined at position 12. The previously identi¢ed cDNA fragment
located in the 3PUTR at position 1742^2008 is indicated with an underline. B: Alignment of amino acids sequences of PRG3 and oxidoreduc-
tases. Identical amino acids are highlighted in white against a black background, and similar amino acids are shown against a gray back-
ground. rubB: E. coli rubredoxin NADþ reductase, GenBank accession number C65051, CAMA: P. putida putidaredoxin reductase, GenBank
accession number P16640, slr1743: Synechocystis sp. NADH dehydrogenase, GenBank accession number S74822, AIF: Homo sapiens AIF,
GenBank accession number AAD16436. C: Chromosomal localization of PRG3 gene. The genomic DNA fragment containing the PRG3 gene
was labeled with digoxigenin-dUTP and hybridized to synchronized human lymphocyte metaphase spreads. The probe was shown to localize to
10q21.3^q22.1 (arrows) as judged by counterstaining with DAPI and actinomycin D (for a DA-DAPI banding pattern) or PI (for an R banding
pattern, shown).
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into HeLa cells. Twenty-four hours post-transfection, cells were ¢xed
and the localization of the expressed FLAG-PRG3 protein was iden-
ti¢ed by immunostaining with an anti-FLAG antibody (M2, Sigma)
followed by detection with a FITC-conjugated anti-mouse IgG anti-
body. Mitochondria were visualized by transfecting a pEYFP-Mito
plasmid (Clontech). PRG3-dependent apoptosis was examined in
HeLa cells transfected with 2 Wg of a PRG3 or PRG3vN expression
plasmids together with 0.4 Wg of pmemGFPcon, an expression plas-
mid for membrane-anchored green £uorescent protein (GFP). Three
days after transfection, cells were ¢xed with methanol and stained
with DAPI to observe nuclear morphology using a £uorescent micro-
scope. The percentage of apoptotic cells was determined by dividing
the number of GFP-positive cells with apoptotic nuclear morphology
by the total number of GFP-positive cells. At least 400 cells from four
randomly selected ¢elds were counted in each experiment. Sub-G1
fractions were analyzed by FACS as follows. H1299 cells (2U105
cells/6 cm dish) were co-transfected with PRG3 or PRG3vN expres-
sion plasmids and pmemGFPcon. Three days later, cells were recov-
ered and ¢xed with 70% EtOH followed by PI stain (0.5 Wg/ml). DNA
contents in memGFP-positive cells were analyzed by FACS (FACS
440, Beckton Dickinson, Mountain View, CA, USA).
2.5. Reporter gene assay
H1299 cells (1U105/well) were transfected with pTI-Luc plasmid
containing a p53-responsive element from PRG3 by Lipofectamine
(Life Technology). Two days after transfection, cells were lysed in
Reporter Lysis Bu¡er (Promega, Madison, WI, USA) and luciferase
activities were measured by a luminometer using an Enhanced Lucif-
erase Assay kit (BD Biosciences, San Diego, CA, USA).
2.6. Sequence analysis
Searches of the protein sequence database were performed using the
PSI-BLAST program and COGnitor. Sequence alignment was per-
formed by ClustalW (version 1.7), a multiple sequence alignment pro-
gram, and displayed in BEAUTY. The genomic sequence of PRG3 in
the human chromosome 10 (GI: 15294724) was analyzed for the p53-
responsive element using the FindPatterns program (GCG Wisconsin
Package: Accelrys, Princeton, NJ, USA).
3. Results
3.1. Cloning and structural organization of the PRG3 gene
The PRG3 transcript has been identi¢ed as one of the p53
target genes whose expression is induced in EB1 human colon
cancer cells that undergo p53-dependent apoptosis [35]. EB1
cells were derived from EB cells (p53 3/3) by stable trans-
fection of a wild-type p53-expressing gene under the control
of the rat metallothionein MT-1 promoter. EB1 cells undergo
massive apoptosis upon induction of wild-type p53 by expo-
sure to 0.1 mM ZnCl2 for 2^3 days [48]. To further character-
ize the PRG3 transcript, a cDNA library was constructed
from EB1 cells treated with 0.1 mM ZnCl2 for 9 h and used
for the cDNA cloning. Half a million bacterial colonies were
screened by hybridization using the previously identi¢ed
PRG3 cDNA fragment as a probe. Positive clones were ana-
lyzed and sequenced.
The predicted amino acid sequence revealed that PRG3 en-
codes a novel protein containing 374 amino acids with an
approximate molecular mass of 40.5 kDa (Fig. 1A). The
NH2-terminus of PRG3 (amino acid positions 13^35) contains
a signature motif for the bacterial aromatic ring hydroxylases
(£avoprotein monooxygenases): a conserved dinucleotide-
binding motif that is found associated with a ‘LKL’ fold
[49]. The amino acid sequence of PRG3 shows 24% identity
and 45% similarity with Escherichia coli rubredoxin NADþ
reductase, 26% identity and 41% similarity with Pseudomonas
putida putidaredoxin reductase, and 25% identity and 40%
similarity with Synechocystis NADH dehydrogenase (Fig.
1B). PRG3 does not share any homology with the known
components of the respiratory chain. Instead, it displays a
homology with the recently identi¢ed human AIF [41], with
22% identity and 44% similarity. AIF is a £avoprotein and an
active quinone oxidoreductase with a relative molecular mass
Fig. 2. p53-dependent expression of the PRG3 gene. A: Expression of PRG3 mRNAs in EB1 cells. Total RNA was isolated from EB1 cells at
0, 4, 9, and 13 h after the treatment with 0.1 mM ZnCl2 and analyzed by Northern blotting for the expression of PRG3, p21, and L-actin. B:
PRG3 mRNA is induced by the activation of endogenous p53. Human lymphoblast TK6 (p53 +/+) cells were exposed to 0.2 Wg/ml doxorubi-
cin for 15 h. Total RNA was isolated from cells and analyzed for the expression of the PRG3 (top) and p21/Waf1 (middle) genes by Northern
blotting. The staining pattern of RNA by methylene blue is shown (bottom).
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of 57 kDa. AIF is normally con¢ned to mitochondria, but
translocates to the nucleus after being released from mito-
chondria upon induction of apoptosis. Unlike AIF, the pre-
dicted amino acid sequence of PRG3 does not contain an
obvious mitochondrial or nuclear localization sequence.
3.2. Chromosomal localization of the PRG3 gene
A genomic DNA fragment containing the PRG3 gene was
isolated from a human BAC genomic DNA library by hybrid-
ization screening using PRG3 cDNA as a probe. The identity
of the genomic DNA fragment was con¢rmed by partial se-
quencing (data not shown). The fragment was labeled with
digoxigenin-dUTP and hybridized to synchronized human
lymphocyte metaphase spreads. The probe was shown to lo-
calize to 10q21.3^q22.1 as judged by both DA-DAPI and PI
banded metaphase chromosomes (Fig. 1C). These results also
indicate that the PRG3 gene is a unique gene. This region is
mutated in a variety of cancers, including thyroid, leukemia,
uterus, lung, ovary, large intestine, breast, brain, and bladder
(Recurrent Chromosome Aberrations in Cancer, Mitelman
Database of Chromosome Aberrations in Cancer (2001)
Mitelman, F., Johansson, B. and Mertens, F. (Eds.), http://
cgap.nci.nih.gov/Chromosomes/Mitelman). Thus, it is possible
that mutations to the PRG3 gene could contribute to human
tumorigenesis.
3.3. Expression of the PRG3 gene induced by p53
The expression pro¢le of the PRG3 gene in EB1 cells was
studied by Northern blotting. Total RNA was prepared from
EB1 cells treated with 0.1 mM ZnCl2 for 0, 4, 9 and 13 h.
Hybridization was performed using a cDNA fragment of the
PRG3-coding region as a probe (Fig. 2A). Northern blotting
revealed two transcripts expressed from the PRG3 gene fol-
lowing p53 induction. The larger mRNA, that has already
been reported [35], is about 4.0 kb in length, and the shorter
mRNA is approximately 1.8 kb. This shorter mRNA seems to
be the major PRG3 transcript in EB1 cells. The induction of
both PRG3 mRNAs was detectable at 4 h after the induction
of p53. The maximum level of PRG3 mRNAs was reached in
9^13 h, which is slower than p21/Waf1 gene where the max-
imum level of expression was reached 4 h after the induction
of p53. Only the larger mRNA (4.0 kb) was detectable with
the probe containing the 3P-untranslated region (UTR) of the
PRG3 cDNA [48], indicating that the two PRG3 mRNAs
share a common coding sequence, but di¡er in their 3PUTR.
The induction of PRG3 gene expression by p53 was exam-
ined in a TK6 (p53 +/+) human lymphoblast cell line. These
cells retain wild-type p53 genes and the activation of p53 by
ionizing radiation or chemotherapy drugs, such as doxorubi-
cin, induces p53-dependent apoptosis. Cells were exposed to
doxorubicin (0.2 Wg/ml) for 15 h and total RNA was extracted
from the cells. The expression of PRG3 was analyzed by
Northern blotting (Fig. 2B). The PRG3 mRNA (4.0 kb tran-
script) was signi¢cantly induced by the induction of p53-de-
pendent apoptosis induced by doxorubicin. The expression of
Waf1/p21 was also induced under these experimental condi-
tions. Thus, the expression of PRG3 gene is induced by the
activation of authentic p53 after DNA is damaged, and the
PRG3 gene is a potential PRG in p53-dependent apoptosis.
3.4. Identi¢cation of a p53-responsive element in the PRG3
gene
To determine whether p53 directly regulates PRG3 gene
expression, we analyzed the entire genomic sequence for the
presence of a p53 consensus sequence. This gene contains
nine exons and the entire genomic sequence was subjected
to FindPatterns analysis with the p53 consensus sequence
(RRRCWWGYYYN(1^10)RRRCWWGYYY). We identi¢ed
a 35 bp element containing two overlapped p53-DNA binding
sites (Fig. 3A). Next, we analyzed whether this 35 bp element
Fig. 3. Identi¢cation of p53-responsive element in PRG3 gene. A:
Genomic structure of PRG3 gene. PRG3 gene contains nine exons
as indicated with black boxes. An identi¢ed p53-responsive element
was shown with the alignment of p53-binding site consensus se-
quence. Asterisks and upper cases are matched sequence and lower
cases indicate unmatched sequence with the consensus. B: Reporter
gene assay for the p53-responsive element in PRG3 gene. Luciferase
reporter plasmid containing a 25 bp p53-responsive element identi-
¢ed in PRG3 was co-transfected into H1299 (p53 3/3) cells with
an empty vector, wild-type p53 expression plasmid, or R175H mu-
tant p53 expression plasmid. Luciferase activities were measured
after 2 days of transfection. Mean values of the results of three ex-
periments are shown with error bars of standard deviations.
Fig. 4. Expression pro¢le of PRG3 gene in human tissues. A human
multiple tissue Northern blot was probed with a cloned PRG3
cDNA. Lanes: 1, heart; 2, brain; 3, placenta; 4, lung; 5, liver; 6,
skeletal muscle; 7, kidney; 8, pancreas.
FEBS 26324 19-7-02
Y. Ohiro et al./FEBS Letters 524 (2002) 163^171 167
is transcriptionally responsive to p53 in a reporter gene assay.
This fragment was cloned into the promoter region of the
luciferase expression plasmid pTI-Luc. The luciferase activity
was measured 2 days after transfection of pTI-Luc alone and
in combinations with wild-type p53 or with R175H transacti-
vation-dead mutant p53 expression plasmids. The luciferase
activity was induced ¢ve-fold by co-transfection with the
wild-type p53 expression plasmid. In the control co-transfec-
tion experiments with a R175H transactivation-dead mutant
p53 expression plasmid, the luciferase activity was not induced
(Fig. 3B). Collectively, these results support the hypothesis
that the expression of the PRG3 gene in cells undergoing
p53-dependent apoptosis involves direct activation of its pro-
moter by p53.
3.5. Expression of PRG3 mRNA in human tissues
The expression pattern of the PRG3 gene in normal human
tissues was studied using human multiple tissue Northern
blots prepared from a variety of human tissues (Clontech).
Both 4.0 kb and 1.8 kb mRNAs were detected in most tissues
(Fig. 4). The highest level of PRG3 mRNA was detected in
the heart; moderate levels were observed in the liver and
skeletal muscles, and low levels of expression were observed
in the placenta, lung, kidney, and pancreas. The expression of
PRG3 mRNA was barely detectable in the brain. These re-
sults demonstrate that the relative expression levels of PRG3
mRNA vary in human tissues: a clear contrast to that of AIF
where the expression is ubiquitous.
3.6. PRG3 is a cytoplasmic protein
The predicted amino acid sequence of the PRG3 protein
has a homology to human and mouse AIF, but lacks a mi-
tochondrial localization signal peptide. The localization of the
PRG3 protein in the cell was therefore studied. A full-length
FLAG-tagged PRG3 protein was expressed in HeLa cells by
transient transfection. Twenty-four hours post-transfection,
cells were ¢xed and the over-expressed FLAG-PRG3 protein
was identi¢ed by immuno£uorescent staining with an anti-
FLAG antibody. The pEYFP-Mito plasmid, which expresses
the yellow £uorescent protein (YFP) in mitochondria, was
used to visualize them. As shown in Fig. 5, FLAG-PRG3
clearly localized to the cytoplasm and its distribution pattern
is di¡erent from YFP-Mito in the mitochondria. These results
demonstrate that, in contrast to AIF, PRG3 is a cytoplasmic
and not a mitochondrial protein.
3.7. Ectopic expression of PRG3 induces apoptosis and its
conserved ADP-binding motif is dispensable for its
apoptotic function
The PRG3 gene is a potential p53 target gene in a p53-
dependent apoptosis pathway. The PRG3 protein shares a
signi¢cant sequence homology with the apoptogenic protein
AIF. Thus, we tested if PRG3 protein induces apoptosis in
cells. In a set of transient transfection experiments, we quan-
ti¢ed the e¡ect of ectopic over-expression of PRG3 on apo-
ptosis in HeLa cells. Cells received the PRG3 expression plas-
mid together with a membrane-anchored GFP (memGFP)
expression plasmid as a transfection marker. Three days after
transfection, cells were ¢xed and stained with DAPI to gauge
for apoptosis by monitoring nuclear morphology changes in
the GFP-positive cells using a £uorescent microscope. As
shown (Figs. 6A,B), over-expression of the PRG3 protein in-
duced apoptotic nuclear morphology in 30% of the HeLa cells
(Fig. 6A, panel 2, arrows, and Fig. 6B, lane 2). Transfection
with a mixture of empty expression vector and memGFP ex-
pression vector (negative control) caused nuclear fragmenta-
tion in approximately 10% of the cells (Fig. 6A, panel 1 and
Fig. 6B, lane 1). We observed apoptotic nuclear morphology
in more than 50% of the p53-transfected cells (Fig. 6A, panel
4 and Fig. 6B, lane 4) under these conditions.
The predicted PRG3 protein sequence revealed a highly
conserved NH2-terminal domain found in oxidoreductases
from various organisms (Fig. 1B). This region of PRG3 (ami-
no acids 13^35) contains a signature motif for the conserved
ADP-binding motif, which is essential for the enzymatic ac-
tivity. We examined the contribution of the oxidoreductase
activity of PRG3 to its apoptotic function. We constructed
an NH2-terminal (1^37) deletion mutant (PRG3vN), which
lacks the putative oxidoreductase activity of PRG3. The
PRG3vN expression plasmid was co-transfected with the
memGFP-expressing plasmid into HeLa cells as described
above, and the nuclear morphologies of transfected cells
were analyzed. The ectopic expression of PRG3vN protein
induced apoptosis in HeLa cells at almost the same level as
Fig. 5. PRG3 is a cytoplasmic protein. FLAG-tagged PRG3 protein
was expressed in HeLa cells by transient transfection. Twenty-four
hours after transfection, cells were ¢xed and the localization of the
expressed FLAG-PRG3 protein was identi¢ed by immunostaining
with anti-FLAG antibody. For comparison, mitochondria were visu-
alized by transfecting the pEYFP-Mito plasmid that expresses the
YFP tagged with a mitochondria-targeting sequence adopted from
subunit VIII of cytochrome c oxidase. YFP £uorescence was ob-
served through the FITC £uorescence-¢lter set.
C
Fig. 6. PRG3 and its NH2-terminal deletion mutant induce apoptosis in cells. A: Induction of apoptosis by ectopic expression of PRG3. Plas-
mids expressing PRG3, NH2-terminal deletion mutant PRG3 (PRG3vN), or p53 were co-transfected with one-¢fth the amount of a membrane-
anchored GFP-expressing plasmid into HeLa cells. Three days after transfection, the nuclear morphology of GFP-positive cells was visualized
by DAPI staining. Apoptotic cells are indicated by arrowheads. B: The percentage of apoptotic cells with S.D. was calculated from the results
of A (lane numbers correspond to A). GFP: 10.6V 4.2%, PRG3: 29.3V 3.5%, PRG3vN: 25.2V 1.6%, p53: 52.5V 1.6%. C: Ectopic expression
of PRG3 and the NH2-terminal deletion mutant PRG3 induce apoptosis in cells. PRG3 or PRG3vN expression plasmids were transfected into
H1299 cells together with memGFP expression plasmid. Cells were recovered 3 days after transfection and stained with PI (0.5 Wg/ml). The
DNA content of each cell was analyzed by FACS. The percentile of sub-G1 fraction is shown in each panel. Panel 1: memGFP alone, panel
2: PRG3, panel 3: PRG3vN, panel 4: p53.
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that induced by wild-type PRG3 (Fig. 6A, panel 3 and Fig.
6B, lane 3).
We further con¢rmed apoptosis in cells induced by the ex-
pression of the PRG3 protein by FACS analyses measuring
sub-G1 fractions. Expression plasmids for PRG3 or PRG3vN
were transfected into H1299 (p53 3/3) cells together with the
memGFP-expressing plasmid. Three days after transfection,
cells were ¢xed and stained with PI. The DNA content of
memGFP-positive cells was analyzed by FACS and a sub-
G1 fraction was quanti¢ed. The expression of both PRG3
and PRG3vN increased the sub-G1 fraction to 28.1% and
35.2%, respectively (Fig. 6C, panels 2 and 3), whereas the
expression of memGFP showed 17.1% of sub-G1 fraction
(Fig. 6C, panel 1). The expression of p53 showed 53.5% of
sub-G1 fraction under the same conditions (Fig. 6C, panel 4).
The proportions of apoptotic cells judged by the sub-G1 pop-
ulation correlated well with those measured by counting apo-
ptotic nucleus in HeLa cells (Fig. 6A,B). These results clearly
indicate that the ectopic expression of PRG3 induces apopto-
sis and that the NH2-terminal domain of PRG3 does not
contribute to the apoptotic function of PRG3. Therefore,
the oxidoreductase activity of PRG3 is most likely dispensable
for its apoptotic function.
4. Discussion
Activation of a cell death cascade is one of the key mech-
anisms by which p53 functions as a tumor suppressor. The
e¡ects of p53 are largely due to its transcription activation
function because no mutant p53 so far isolated functions as
a transcription activator as does wild-type p53. However, the
downstream events of p53 in the process of apoptosis are still
not completely understood.
We have identi¢ed a novel p53 target gene, PRG3. The
expression of this gene was induced by endogenous p53, acti-
vated by DNA damage caused by doxorubicin. Furthermore,
the PRG3 gene contains a putative p53-responsible element in
its intron, which is a similar feature found in several other p53
target genes including Mdm2 and p53AIP. Therefore, it is
likely that the induction of PRG3 expression is directly acti-
vated by p53 (Fig. 3). The activation of PRG3 gene in EB1
cells after the initiation of p53-dependent apoptosis is slower
than that of p21/Waf1 (Fig. 2). This might mean that the
binding a⁄nity of p53 to the p53-responsible element in the
PRG3 gene is lower than that of the p21/Waf1 gene in cells
[50].
The mRNA for PRG3 is highly expressed in heart, liver,
and skeletal muscles where the level of p53 expression is al-
most undetectable. It is unlikely that the highly expressed
PRG3 mRNA in a normal human heart induces apoptosis
(Fig. 4). PRG3 expressed in the heart, as well as expressed
in other organs at a low level, may function as an oxidore-
ductase in their metabolic systems, or there may be a regula-
tory factor(s) or both, to suppress the apoptotic function of
the protein. Recently, it has been shown that an apoptotic
function of AIF is inhibited by heat shock protein 70
(HSP70) [51]. That PRG3 over-expression does not induce
apoptosis in 293 cells (Ohiro et al., unpublished observation),
where HSP70 protein is constitutively and highly expressed
[52], raises the possibility that the apoptotic function of
PRG3 is also inhibited by HSP70. Alternatively, there may
be organ-speci¢c PRG3 inhibitors expressed. For example,
many small heat shock proteins are predominantly expressed
in heart and skeletal muscle [53], including recently identi¢ed
HspB8/H11, a serine-threonine protein kinase whose expres-
sion is associated with cell growth [54,55]. Nevertheless, it is
likely that the high level of expression of the PRG3 gene in
the heart is achieved through a molecule other than p53. This
suggests that there may be additional regulatory mechanisms
that lead to high levels of PRG3 expression in the heart.
PRG3 protein shares homology with oxidoreductases, in-
cluding the proapoptotic protein AIF (Fig. 1B); however, it
does not show homology with PIG3, another p53 target gene
sharing homology with oxidoreductases from several species
[39]. The over-expression of the PRG3 protein was found to
induce apoptosis in cells (Fig. 6). Various possibilities could
be envisioned to explain how PRG3 initiates cell death. It has
been reported that the expression of NADH quinone oxido-
reductase 1 stabilizes p53 by inhibiting its degradation and
therefore accelerates p53-dependent apoptosis in the cell
[56]. This stabilization of p53 requires its oxidoreductase ac-
tivity, and thus PRG3 may also stabilize p53 to support p53-
dependent apoptosis. At present, it is not clear whether PRG3
is a £avoprotein; however, the putative oxidoreductase func-
tion of PRG3 protein is dispensable to the activity of PRG3
to induce apoptosis. The PRG3 NH2-terminal deletion mu-
tant lacking the putative ADP-binding domain e¡ectively in-
duced apoptosis, indicating that the ADP-binding domain,
which is essential for the oxidoreductase activity, is not im-
portant for its apoptotic function (Fig. 6). Thus the domain
responsible for the induction of apoptosis in PRG3 should be
located within the rest of the molecule. Similar results have
been reported for AIF. The AIF protein, lacking NAD oxi-
dase activity after removing the FAD cofactor from its mol-
ecule, retains full apoptotic function [41]. Deletion mutant
analysis of AIF suggests that the structure ^ or at least a
part of the oxidoreductase protein structure ^ but not the
enzyme activity is important for its apoptotic function [44].
The process of p53-dependent apoptosis requires mitochon-
dria-dependent apoptotic machinery, including Apaf-1 and
caspase-9, as well as the release of cytochrome c from the
mitochondria [57], and is therefore a caspase-dependent mech-
anism. A p53 homologue recently identi¢ed in Caenorhabditis
elegans revealed the existence of p53-dependent apoptosis
without caspase activation [58]. Moreover, p53 has been
shown to translocate into mitochondria upon the induction
of apoptosis, and is directly involved in releasing cytochrome
c from mitochondria [59]. Although it is not presently clear
that translocation of p53 in mitochondria also releases AIF
from mitochondria, it is possible that caspase-independent
apoptosis will be initiated by p53 if AIF is released from
mitochondria by such a mechanism. AIF is a proapoptotic
mitochondrial protein that translocates into the nucleus after
being released from mitochondria to initiate caspase-indepen-
dent apoptosis by inducing chromatin condensation or DNA
fragmentation in nuclei [43,44]. It is unclear how PRG3 in-
duces apoptosis in cells. Like AIF or cytochrome c, PRG3
seems to be a phylogenetically old, bi-functional protein
with an electron acceptor/donor (oxidoreductase) function
and an independent apoptotic function. PRG3 shares homol-
ogy with the mature form of AIF that is processed from its
proapoptotic form by removing 102 NH2-terminal residues
responsible for mitochondrial localization (Fig. 1B). Lack of
the mitochondrial localization signal in the PRG3 sequence
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prevents the protein from entering mitochondria (Fig. 5). Sim-
ilarly, it is not clear whether PRG3 translocates into the nu-
cleus, as does AIF, to induce apoptosis since PRG3 does not
have an obvious nuclear localization signal sequence. The
structural similarity between mature AIF and PRG3 raises
the possibility that PRG3 may be involved in a p53-dependent
and caspase-independent apoptosis mechanism.
Cell death activated by p53 is stimulated by cellular stresses
such as DNA damage and hypoxia. Moreover, the activation
of p53-dependent apoptosis by stresses is thought to be a
mechanism by which many chemotherapeutic agents act on
human tumors. Therefore, understanding the p53-mediated
apoptosis pathway is crucial, not only for understanding its
mode of tumor suppression, but also for devising new cancer
therapies aimed at reconstituting the apoptotic response in
many tumors. As more than 50% of human cancers lack
wild-type p53, PRG3 may be an attractive new candidate
for study as a gene mediating a p53-dependent apoptotic re-
sponse.
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